Imugene, an immuno-oncology company focusing on cancer vaccines and immunotherapies, has also joined forces with MaxCyte to enhance their cancer immunotherapy programs. Utilizing MaxCyte?s Flow Electroporation? technology and ExPERT? platform, Imugene aims to advance azer-cel, a potential first-in-class allogeneic CD19 CAR-T product candidate, geared towards treating blood cancers. In addition to azer-cel, Imugene is exploring other novel cell therapy programs, leveraging MaxCyte's platforms to innovate and expedite therapeutic development.